Trastuzumab deruxtecan for HER2-overexpressing colorectal cancer

What is the Purpose of this Study?

If you choose to join this study, you will:
- Get the study drug, trastuzumab deruxtecan, by I.V. once every 3 weeks
- Give blood and urine samples
- Have regular CT or MRI scans
What is the Condition Being Studied?
Colorectal Adenocarcinoma

Who Can Participate in this Study?

Adults with colorectal adenocarcinma who:

- Have advanced or metastatic disease

- Failed standard-of-care therapy

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to see if the study drug, trastuzumab deruxtecan, is safe and effective for fighting your cancer. We will also compare 2 different dose levels.

Study Details

Full Title
[DS8201-A-U207] A phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-overexpressing locally advanced, unresectable or metastatic colorectal cancer (Destiny-CRC02)
Principal Investigator

Protocol Number
IRB:
PRO00107696

NCT:
NCT04744831
ClinicalTrials.gov
View on ClinicalTrials.gov